Guangzhou Kingmed Diagnostics Group Future Growth
Future criteria checks 3/6
Guangzhou Kingmed Diagnostics Group is forecast to grow earnings and revenue by 44.9% and 10.4% per annum respectively. EPS is expected to grow by 45.2% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
44.9%
Earnings growth rate
45.2%
EPS growth rate
| Healthcare earnings growth | 22.8% |
| Revenue growth rate | 10.4% |
| Future return on equity | 8.7% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Guangzhou Kingmed Diagnostics Group (SHSE:603882) Has A Pretty Healthy Balance Sheet
Dec 13
Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06Earnings Tell The Story For Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Sep 27Guangzhou Kingmed Diagnostics Group Co., Ltd. Just Missed Revenue By 9.5%: Here's What Analysts Think Will Happen Next
Sep 03Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?
Aug 25A Look At The Fair Value Of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Jun 04Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings
May 02Investors Don't See Light At End Of Guangzhou Kingmed Diagnostics Group Co., Ltd.'s (SHSE:603882) Tunnel And Push Stock Down 26%
Apr 17Investor Optimism Abounds Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) But Growth Is Lacking
Feb 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 10,040 | 943 | 1,115 | 1,507 | 12 |
| 12/31/2025 | 8,859 | 694 | 372 | 1,610 | 13 |
| 12/31/2024 | 7,609 | 239 | 455 | 1,735 | 9 |
| 9/30/2024 | 7,849 | 161 | 532 | 1,035 | N/A |
| 6/30/2024 | 8,251 | 448 | 279 | 911 | N/A |
| 3/31/2024 | 8,263 | 475 | 195 | 873 | N/A |
| 12/31/2023 | 8,540 | 643 | 516 | 1,231 | N/A |
| 9/30/2023 | 9,578 | 882 | 342 | 1,126 | N/A |
| 6/30/2023 | 11,052 | 1,397 | 729 | 1,448 | N/A |
| 3/31/2023 | 13,342 | 2,054 | 1,325 | 2,077 | N/A |
| 12/31/2022 | 15,476 | 2,755 | 1,107 | 1,948 | N/A |
| 9/30/2022 | 15,534 | 2,996 | 1,463 | 2,352 | N/A |
| 6/30/2022 | 14,800 | 2,803 | 1,349 | 2,325 | N/A |
| 3/31/2022 | 13,516 | 2,532 | 1,018 | 2,018 | N/A |
| 12/31/2021 | 11,943 | 2,220 | 1,136 | 2,088 | N/A |
| 9/30/2021 | 11,034 | 2,127 | 787 | 1,646 | N/A |
| 6/30/2021 | 10,225 | 2,013 | 1,176 | 1,900 | N/A |
| 3/31/2021 | 9,752 | 2,000 | 1,176 | 1,802 | N/A |
| 12/31/2020 | 8,244 | 1,510 | 972 | 1,523 | N/A |
| 9/30/2020 | 7,176 | 1,138 | 807 | 1,240 | N/A |
| 6/30/2020 | 6,201 | 787 | 383 | 745 | N/A |
| 3/31/2020 | 5,276 | 408 | 236 | 555 | N/A |
| 12/31/2019 | 5,269 | 402 | 386 | 661 | N/A |
| 9/30/2019 | 5,128 | 388 | 323 | 635 | N/A |
| 6/30/2019 | 4,954 | 309 | 254 | 571 | N/A |
| 3/31/2019 | 4,771 | 266 | 226 | 558 | N/A |
| 12/31/2018 | 4,525 | 233 | 183 | 530 | N/A |
| 9/30/2018 | 4,309 | 205 | 51 | 384 | N/A |
| 6/30/2018 | 4,107 | 200 | N/A | 340 | N/A |
| 3/31/2018 | 3,909 | 191 | N/A | 289 | N/A |
| 12/31/2017 | 3,792 | 189 | N/A | 284 | N/A |
| 9/30/2017 | 3,689 | 198 | N/A | 292 | N/A |
| 12/31/2016 | 3,222 | 170 | N/A | 292 | N/A |
| 9/30/2016 | 3,010 | 153 | N/A | 253 | N/A |
| 12/31/2015 | 2,389 | 140 | N/A | 220 | N/A |
| 12/31/2014 | 1,838 | 71 | N/A | 226 | N/A |
| 12/31/2013 | 1,356 | 52 | N/A | 76 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603882's forecast earnings growth (44.9% per year) is above the savings rate (2.8%).
Earnings vs Market: 603882's earnings (44.9% per year) are forecast to grow faster than the CN market (25.4% per year).
High Growth Earnings: 603882's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603882's revenue (10.4% per year) is forecast to grow slower than the CN market (13.7% per year).
High Growth Revenue: 603882's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603882's Return on Equity is forecast to be low in 3 years time (8.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:47 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangzhou Kingmed Diagnostics Group Co., Ltd. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hao Wu | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |